Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 313-319

  Ohira, Masahiro ^a   Yamaguchi, Takashi ^a   Saiki, Atsuhito ^a   Ban, Noriko ^a   Kawana, Hidetoshi ^a   Nagumo, Ayako ^a   Murano, Takeyoshi ^a   Shirai, Kohji ^b   Tatsuno, Ichiro ^a  

^a TOHO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

Arterial stiffness; Biguanide; Blood pressure; Cardiovascular disease; Sulfonylurea; Thiazolidinediones

Indexed keywords

ADIPONECTIN; ALBUMIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE;

ADD ON THERAPY; ADULT; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARTICLE SIZE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

EID: 84905116036     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S65275     Document Type: Article

References (32)

1. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care.2000;23:962-968.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type2 diabetes (UKPDS35): prospective observational study. BMJ.2000;321: 405-412.
3. [No authors listed]. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2diabetes (UKPDS33). Lancet.1998;352:837-853.
4. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in type1and2diabetes mellitus: meta-analysis of randomized trials. Am Heart J.2006;152:27-38.
5. [No authors listed]. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in over weight patients with type2diabetes (UKPDS34). Lancet.1998;352:854-865.
6. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res.2008;5:157-167.
7. Koenig W, Karakas M, Zierer A, et al. Oxidized LDL and the Risk of Coronary Heart Disease: Results from the MONICA/KORA Augsburg Study. Clin Chem.2011;57:1196-1200.
8. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type2diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab.2001;86:1930-1935.
9. Saiki A, Oyama T, Endo K, et al. Preheparin serum lipoprotein mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract. 2007;76:93-101.
10. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferatoractivated receptor aonist. Diabetes.2005;54:2460-2470.
11. Shakuto S, Oshima K, Tsuchiya E. Glimepiride exhibits prophylactic effect on atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2005;182:209-217.
12. Subramanian V, Golledge J, Ijaz T, Bruemmer D, Daugherty A. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. Circ Res. 2010;107:953-958.
13. Shirai K, Itoh Y, Sasaki H, et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract.1999;46:35-41.
14. Kato T, Sawai Y, Kanayama H, et al. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes.2009;117: 593-599.
15. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressureindependent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atherosclerosis Thromb.2006;13:101-107.
16. Takaki A, Ogawa H, Wakayama T, et al. Cardio-ankle vascular index is a new noninvasive parameter of arterial stiffness. Circ J.2007;71: 1710-1714.
17. Shirai K, Song M, Suzuki J, et al. Contradictory effects of β1-and α1-aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI)-CAVI independent of blood pressure. J Atheroscler Thromb.2011;18:49-55.
18. Kubozono T, Miyata M, Ueyama K, et al. Clinical significance and reproducibility of new arterial distensibility index. Circ J.2007;71: 89-94.
19. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J.2008;72:598-604.
20. Shirai K, Nema T, Hiroh Y, Itoh Y, Miyashita Y, Watanabe H. Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterols. J Clin Lab Anal.1997;11: 82-86.
21. Kobayashi J, Hashimoto H, Fukamachi I, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta.1993;216: 113-123.
22. Ohira M, Endo K, Oyama T, et al. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human inuslin30/70 to biphasic insulin aspart30/70. Metabolism.2011;60: 78-85.
23. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta.1994;1215: 121-125.
24. Mead MG, Dangerfield WG. The investigation of midband lipoproteins using polyacrylamide gel electrophoresis. Clin Chim Acta.1974;51: 173-182.
25. Miwa K. Low density lipoprotein particles are small in patients with coronary vasospasm. Int J Cardiol.2003;87:193-201.
26. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type2diabetes: a randomized trial. JAMA.2006;296:2572-2581.
27. Nissen SE, Nicholls SJ, Wolski K, et al; PERISCOPE investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type2 diabetes: the PERISCOPE randomized controlled trial. JAMA.2008;299:1561-1573.
28. Yoon JH, Kim SK, Choi HJ, et al. Adiponectin provides additional information to conventional cardiovascular risk factors for assessing the risk of atherosclerosis in both genders. PLoS One.2013;8:e75535.
29. Reinstadler S, Klug G, Feistritzer H, et al. Relation of plasma adiponectin levels and aortic stiffness after acute ST-segment elevation myocardial infarction. Eur Heart J Acute Caridiovasc Care.2014;3:10-17.
30. Austin MA, Breslow JA, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low density lipoprotein subclass pattern and risk of myocardial infarction. J Am Med Assoc.1988;260:1917-1921.
31. Nagayama D, Endo K, Ohira M, et al. Effects of body weight reduction on carido-ankle vascular index (CAVI). Obes Res Clin Pract. 2013;7:e89-e164.
32. Nagayama D, Saiki A, Endo K, et al. Improvement of cardio-ankle vascular index by glimepiride in type2diabetic patients. Int J Clin Pract.2010;64:1796-1801.